dopamine

AbbVie
Pharma

AbbVie notches FDA nod for Ceverel asset Juvmo in Parkinson's

Through a trial setback looms in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics has paid off with its first approval from the FDA.
Fraiser Kansteiner Sep 28, 2026 8:15am